Fresh analysis suggests that patients who come off popular weight-loss injections like semaglutide or tirzepatide may regain lost weight much more quickly than those who end conventional diet and exercise plans.
Published data in a leading medical journal demonstrates that while obese individuals often shed substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit.
"People using such medications must be cognizant of the risk of fast weight regain when the treatment ends," warns expert Dr. Susan Jebb.
Such speed of recovery implies a return to starting mass in about a year and a half.
Weighing Treatments
The study, which reviewed 37 of trials involving over 9,000 of participants, contrasted the results of the injectable medications with older methods.
Researchers emphasize that people who shed pounds through diet and exercise usually see a less rapid creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Experts propose the mechanism of the jabs explains the amplified regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement results in appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, considering the significant potential of weight regain, the treatment is often ongoing.
This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the chronic nature of obesity," akin to managing conditions like high blood pressure.
User Experiences
Users who have come off the medication report a sudden return of cravings.
"I experienced a trigger that goes on and I was suddenly ravenous," said a patient.
The struggle is exacerbated if patients have not established sustainable lifestyle or habit modifications during treatment.
Significant Use
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Use is more common among females compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone fix and long-term success hinges on ongoing behavioural support.
